JPM: Pharma Must Change Tone Deaf Message On Pricing
This article was originally published in Scrip
Executive Summary
When biopharma executives were asked during the 34th Annual J.P. Morgan Healthcare Conference what they thought of public concerns about prescription drug pricing, some dismissed it as a political issue and others offered the same old explanations about recovering the cost of developing innovative medicines, yet the industry appears dismayed about the ongoing uproar.
You may also be interested in...
Industry Tightens Drug Pricing Message, But Loose Ends Remain
Drug makers are under increasing pressure regarding the cost of their medicines, but instead of pointing fingers at payers for patients' out-of-pocket costs, the industry has shifted to a more collaborative tone, although some tensions will take time to overcome.
BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco
Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.